ERBB2 and non-small cell lung carcinoma: Furthermore, our results suggest that phenotypic plasticity could lead to the same consequences as genetic alterations since the results of retrospective studies did not argue in favor of the use of ICI as a therapeutic strategy in NSCLC patients carrying HER2 mutations (5).